Company Interpace Diagnostics Group Inc Nasdaq
Equities
US46062X1054
Managed Healthcare
End-of-day quote
Other stock markets
|
||
- USD | - |
05-09 | Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-07 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Diagnostic Clinical Services
100.0
%
| 32 | 100.0 % | 40 | 100.0 % | +26.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 32 | 100.0 % | 40 | 100.0 % | +26.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Burnell
CEO | Chief Executive Officer | 62 | 30/11/20 |
Director of Finance/CFO | 32 | 31/05/19 | |
Nicole Massoll
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | - | |
Jody Campbell
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Vijay Aggarwal
BRD | Director/Board Member | 75 | 31/01/22 |
Joseph Keegan
BRD | Director/Board Member | 71 | 31/12/15 |
Stephen Sullivan
BRD | Director/Board Member | 77 | 31/08/04 |
Fortunato Rocca
BRD | Director/Board Member | 62 | 21/01/20 |
Thomas Burnell
CEO | Chief Executive Officer | 62 | 30/11/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 47,000 | 0 | 0 | 72.17 % |
Stock B | 1 | 4,472,442 | 3,227,921 ( 72.17 %) | 96,044 ( 2.147 %) |
Company contact information
Interpace Biosciences, Inc.
Waterview Plaza Suite 310
07054, Parsippany
+855 776 6419
http://www.interpacediagnostics.comSector
1st Jan change | Capi. | |
---|---|---|
-1.12% | 6.43B | |
+4.13% | 1.3B |
- Stock Market
- Equities
- IDXG Stock
- Stock
- Company Interpace Diagnostics Group Inc